Proposal for classifying the acute emetogenicity of cancer chemotherapy

Journal of Clinical Oncology

Volumn 15, Issue 1, 1997, Pages 103-109

  Hesketh, P J ^a   Kris, M G ^a   Grunberg, S M ^a   Beck, T ^a   Hainsworth, J D ^a   Harker, G ^a   Aapro, M S ^a   Gandara, D ^a   Lindley, C M ^a  

^a ST ELIZABETH'S MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTRETAMINE; ANTINEOPLASTIC AGENT; CARMUSTINE; CHLORAMBUCIL; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DOCETAXEL; EPIRUBICIN; ETOPOSIDE; FLUDARABINE; GEMCITABINE; HYDROXYUREA; IDARUBICIN; IFOSFAMIDE; MITOMYCIN; MITOXANTRONE; PROCARBAZINE; STREPTOZOCIN;

ACUTE DISEASE; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; DISEASE CLASSIFICATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PREDICTION; PRIORITY JOURNAL; PROPHYLAXIS; VOMITING;

EID: 0031025087     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.1.103     Document Type: Article

References (69)

1. Grunberg SM, Hesketh PJ: Control of chemotherapy-induced emesis. N Engl J Med 329:1790-1796, 1993
2. Hesketh PJ: Treatment of chemotherapy-induced emesis in the 1990s: Impact of the 5-HT, receptor antagonists. Support Care Cancer 2:286-292, 1994
3. Perez EA: Review of the preclinical pharmacology and comparative efficacy of 5-hydroxytryptamine-3 receptor antagonists for chemotherapy-induced emesis. J Clin Oncol 13:1036-1043, 1995
4. D'Acquisto R, Tyson LB, Gralla RJ, et al: The influence of a chronic high alcohol intake on chemotherapy-induced nausea and vomiting. Proc Am Soc Clin Oncol 5:257, 1986 (abstr)
5. Hesketh PJ, Plagge P, Bryson JC: Single-dose ondansetron for prevention of acute cisplatin-induced emesis: Analysis of efficacy and prognostic factors, in Bianchi AL, Grelot L, Miller AD, et al (eds): Mechanisms and Control of Emesis. London, United Kingdom, Libbey, 1992, pp 25-26
6. Tonato M, Roila F, Del Favero A: Methodology of antiemetic trials: A review. Ann Oncol 2:107-114, 1991
7. Laszlo J: Treatment of nausea and vomiting caused by cancer chemotherapy. Cancer Treat Rev 9:3-9, 1982
8. Strum SB, McDermed JE, Pileggi J, et al: Intravenous metoclopramide: Prevention of chemotherapy-induced nausea and vomiting. Cancer 53:1432-1439, 1984
9. Craig JB, Powell BL: Review: The management of nausea and vomiting in clinical oncology. Am J Med Sci 293:34-44, 1987
10. Lindley CM, Bernard S, Fields SM: Incidence and duration of chemotherapy-induced nausea and vomiting in the outpatient oncology population. J Clin Oncol 7:1142-1149, 1989
11. Aapro MS: Methodological issues in antiemetic studies. Invest New Drugs 11:243-253. 1993
12. Cubeddu LX, Hoffman IS, Fuenmayor NT, et al: Antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimens. J Clin Oncol 8:1721-1727, 1990
13. Beck TM, Ciociola AA, Jones SE, et al: Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy. Ann Intern Med 118:407-413, 1993
14. 3 receptors, in the treatment of nausea and vomiting associated with cyclophosphamide-based chemotherapies. Am J Clin Oncol 17:137-146, 1994
15. DiBenedetto J Jr. Cubeddu LX, Ryan T, et al: Ondansetron for nausea and vomiting associated with moderately emetogenic cancer chemotherapy. Clin Therapeut 17:1091-1098, 1995
16. Richards B, Newling D, Fossa S, et al: Vincristine in advanced bladder cancer: A European Organization for Research on Treatment of Cancer (EORTC) phase II study. Cancer Treat Rep 67:575-577, 1983
17. Volberding P, Abrams DI, Conant M, et al: Vinblastine therapy for Kaposi's sarcoma in the acquired immunodeficiency syndrome. Ann Intern Med 103:335-338, 1985
18. Depierre A, Lemarie E, Dabouis G, et al: Efficacy of navelbine (NVB) in non-small cell lung cancer (NSCLC). Semin Oncol 16:26-29, 1989
19. Le Chevalier T, Pujol JL, Douillard JY, et al: A three-arm trial of vinorelbine (Navelbine) plus cisplatin, vindesine plus cisplatin, and single-agent vinorelbine in the treatment of non-small cell lung cancer: An expanded analysis. Semin Oncol 21:28-34, 1994
20. Saven A, Lemon RH, Kosty M, et al: 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. J Clin Oncol 13:570-574, 1995
21. Keating MJ: Fludarabine phosphate in the treatment of chronic lymphocytic leukemia. Semin Oncol 17:49-62, 1990
22. Ezdinli EZ, Stutzman L: Chlorambucil therapy for lymphomas and chronic lymphocytic leukemia. JAMA 191:444-450, 1965
23. Fisher B, Carbone P, Economou SG, et al: L-phenylalanine mustard (L-PAM) in the management of primary breast cancer. N Engl J Med 292:117-122, 1975
24. Galton D, Till M, Wiltshaw E: Busulfan (1,4-dimethanesulfonyloxybutane, myleran): Summary of clinical results. Ann NY Acad Sci 68:967-973, 1958
25. Creech RH, Catalano RB, Shah MK, et al: An effective low-dose mitomycin regimen for hormonal- and chemotherapy-refractory patients with metastatic breast cancer. Cancer 51:1034-1040, 1983
26. Veronesi A, Dal Bo V, Lo Re G, et al: Mitomycin C treatment of advanced, hormone-resistant prostatic carcinoma: A phase II study. Cancer Chemother Pharmacol 23:115-116, 1989
27. Hines JD, Zakem MH, Adelstein DJ, et al: Treatment of advanced-stage colorectal adenocarcinoma with fluorouracil and high-dose leucovorin calcium: A pilot study. J Clin Oncol 6:142-146, 1988
28. Laubenstein LJ, Krigel RL, Odajnyk CM, et al: Treatment of epidemic Kaposi's sarcoma with etoposide or a combination of doxorubicin, bleomycin, and vinblastine. J Clin Oncol 2:1115-1120, 1984
29. Walther PJ, Williams SD, Troner M, et al: Phase II study of etoposide for carcinoma of the prostate. Cancer Treat Rep 70:771-772, 1986
30. Cormier Y, Eisenhauer E, Muldal A, et al: Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC). Ann Oncol 5:283-285, 1994
31. Einzig AI, Wiernik PH, Sasloff J, et al: Phase II study and long-term follow-up of patients treated with Taxol for advanced ovarian adenocarcinoma. J Clin Oncol 10:1748-1753, 1992
32. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al: European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High dose versus low-dose and long versus short infusion. J Clin Oncol 12:2654-2666, 1994
33. Abrams JS, Vena DA, Baltz J, et al: Paclitaxel activity in heavily pretreated breast cancer: A National Cancer Institute Treatment Referral Center trial. J Clin Oncol 13:2056-2065, 1995
34. Chevallier B, Fumoleau P, Kerbrat P, et al.: Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: A phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 13:314-322, 1995
35. Fossella FV, Lee JS, Shin DM, et al: Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. J Clin Oncol 13:645-651, 1995
36. Ravdin PM, Burris HA, Cook G, et al: Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 13:2879-2885, 1995
37. Bedikian AY, Weiss GR, Legha SS, et al: Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy. J Clin Oncol 13:2895-2899, 1995
38. Buser K, Ross JA, Piguet D, et al: Oral ondansetron in the prophylaxis of nausea and vomiting induced by oral CMF in women with breast cancer. Ann Oncol 4:475-481, 1993
39. Robinson MRG, Chandrysekran S, Newling DW, et al: Low-dose doxorubicin in the management of advanced carcinoma of the prostate. Br J Urol 55:747-748, 1983
40. Scher H, Yagoda A, Watson RC, et al: Phase II trial of doxorubicin in bidimensionally measurable prostatic adenocarcinoma. J Urol 131:1099-1102, 1984
41. Jain KK, Casper ES, Geller NL, et al: A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J Clin Oncol 3:818-826, 1985
42. Smith IE: Mitoxantrone (Novantrone): A review of experimental and early clinical studies. Cancer Treat Rev 10:103-115, 1983
43. Kramer BS, Gams R, Birch R, et al: Phase II evaluation of mitoxantrone in patients with bronchogenic carcinoma: A Southeastern Cancer Study Group trial. Cancer Treat Rep 68:1295-1296, 1984
44. Cowan JD, Neidhart J, McClure S, et al: Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: A Southwest Oncology Group Study. J Natl Cancer Inst 83:1077-1084, 1991
45. Case D, Jr., Hayes DM, Gerber M, et al: Phase II study of oral idarubicin in favorable histology non-Hodgkin's lymphoma. Cancer Res 50:6833-6835, 1990
46. Manetta A, MacNeill C, Lyter JA, et al: Hexamethylmelamine as a single second-line agent in ovarian cancer. Gynecol Oncol 36:93-96, 1990
47. Wheeler BM, Loehrer PJ, Williams SD, et al: Ifosfamide in refractory male germ cell tumors. J Clin Oncol 4:28-34, 1986
48. Stolinsky DC, Solomon J, Pugh R, et al: Clinical experience with procarbazine in Hodgkin's disease, reticulum cell sarcoma, and lymphosarcoma. Cancer 26:984-990, 1970
49. Chang AE, Shiling DJ, Stillman RC, et al: Delta-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. Ann Intern Med 91:819-824, 1979
50. Santoro A, Tursz T, Mouridsen H, et al: Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: A randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 13:1537-1545, 1995
51. Chlebowski RT, Hestorff R, Sardoff L, et al: Cyclophosphamide (NSC 26271) versus the combination of Adriamycin (NSC 123127), 5-fluorouracil (NSC 19893), and cyclophosphamide in the treatment of metastatic prostatic cancer. Cancer 42:2546-2552, 1978
52. Kasimis BS, Miller JB, Kaneshiro CA, et al: Cyclophosphamide versus 5-fluorouracil, doxorubicin, and mitomycin C (FAM') in the treatment of hormone-resistant metastatic carcinoma of the prostate: A preliminary report of a randomized trial. J Clin Oncol 3:385-392, 1985
53. Pommier Y, Pochat L, Marie JP, et al: High-dose cytarabine in acute leukemia: Toxicity and pharmacokinetics. Cancer Treat Rep 67:371-373, 1983
54. Herzig RH, Wolff SN, Lazarus HM, et al: High-dose cytosine arabinoside therapy for refractory Leukemia. Blood 62:361-369, 1983
55. Marsh JC, DeConti RC, Hubbard SP: Treatment of Hodgkin's disease and other cancers with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962). Cancer Chemother Rep 55:599-606, 1971
56. Ahmann DL, Hahn RG, Bisel HF: Evaluation of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962) in the management of patients with advanced breast cancer. Cancer Chemother Rep 56:93-94, 1972
57. Olver IN, Donehower RC, Van Echo DA, et al: Phase II trial of carboplatin in non-small cell lung cancer. Cancer Treat Rep 70:421-422, 1986
58. Martin M, Diaz-Rubio E, Sanchez A, et al: The natural course of emesis after carboplatin treatment. Acta Oncol 29:593-595, 1990
59. Gralla RJ, Itri LM, Pisko SE, et al: Antiemetic efficacy of high-dose metoclopramide: Randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med 305:905-909, 1981
60. Homesley HD, Gainey JM, Jobson VN, et al: Cisplatin chemotherapy and emesis in patients given metoclopramide and controls. N Engl J Med 307:250-251, 1982
61. Cubeddu LX, Hoffman IS, Fuenmayor NT, et al: Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. N Engl J Med 322:810-816, 1990
62. Cupissol DR, Serrou B, Caubel M: The efficacy of granisetron as a prophylactic anti-emetic and intervention agent in high-dose cisplatin-induced emesis. Eur J Cancer 26:S23-S27, 1990
63. Smith IE, Evans BD, Harland SJ, et al: High-dose cyclophosphamide with autologous bone marrow rescue after conventional chemotherapy in the treatment of small cell lung carcinoma. Cancer Chemother Pharmacol 14:120-124, 1985
64. Gianni AM, Bregni M, Siena S, et al: Recombinant human granulocyte-macrophage colony-stimulating factor reduces hematologic toxicity and widens clinical applicability of high-dose cyclophosphamide treatment in breast cancer and non-Hodgkin's lymphoma. Clin Oncol 8:768-778, 1990
65. Falkson CI, Falkson G, Falkson HC: Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma J Clin Oncol 9:1403-1408, 1991
66. Broder LE, Carter SK: Pancreatic islet cell carcinoma. Ann Intern Med 79:108-118, 1973
67. Moertel CG, Hanley JA, Johnson LA: Steptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med 303:1189-1194, 1980
68. Dameshek W, Weisfuse L, Stein T: Nitrogen mustard therapy in Hodgkin's disease. Blood 4:338-379, 1949
69. Karnofsky DA: Nitrogen mustards in the treatment of neoplastic disease. Adv Intern Med 4:1-75, 1950